A patient-focused 3-part webinar series
Clinical guidelines play a powerful role in shaping how dyslipidaemia is diagnosed and treated. Yet for many patients, caregivers, and advocates, these documents can feel complex or difficult to translate into everyday care.
To bridge this gap, the FH Europe Foundation is launching a three-part webinar series in February 2026 “From Evidence to Everyday Life: Understanding the ESC–EAS Dyslipidaemia Guidelines”.
This free webinar trilogy is designed to empower patients, caregivers, and patient advocates with a clear, accessible understanding of how dyslipidaemia guidelines are developed, what they recommend, and how they can be used to support informed, shared decision-making in clinical care.
Why this webinar trilogy matters
The ESC–EAS Dyslipidaemia Management Guidelines, developed by the European Atherosclerosis Society (EAS) and the European Society of Cardiology (ESC), influence cardiovascular care across Europe and beyond. They help guide decisions on risk assessment, lipid level targets, lifestyle interventions, and medical treatments.
This webinar trilogy will focus on:
- How guidelines are developed
- What the 2019 guidelines recommend
- What has changed in the 2025 focused update
- How patients can use guidelines appropriately—without replacing individual medical advice
Webinar format
All three sessions will have the same patient-friendly format:
- 30-minute expert presentations
- 15-minute moderated discussion and live Q&A
- Clear, jargon-free explanations
- Strong patient representation
Who should attend?
This webinar trilogy is designed for:
- Caregivers and family members
- Patient advocates and community leaders
Webinar 1
Behind the Guidelines: How Medical Recommendations Are Built – and Why They Matter to Patients
📅 12 February 2026 | 6:00 pm CET 👉 Register here
This first webinar explains how European medical guidelines are developed, how evidence is assessed, and how transparency and independence are ensured. It also explores how patients can use guidelines responsibly in real life.
Key topics include:
- What clinical guidelines are—and how they differ from individual medical advice
- Collaboration between ESC and EAS
- Differences between European and national guidelines
- The role of evidence, expert panels, and patients
- Conflict of interest management and industry safeguards
- How long guideline development and updates take
- Dos and don’ts of guideline use in everyday care
Speakers
- Prof. Børge Nordestgaard, Copenhagen University Hospital and EAS President (Denmark)
- Prof. Albert Wiegman, Amsterdam UMC, and FH Europe Foundation Trustee (Netherlands)
- Patient representative: Elsie Evans, Ambassador Programme Project Manager, FH Europe Foundation (United Kingdom/South Africa)
- Moderated by Magdalena Daccord, Chief Executive Officer, FH Europe Foundation (Switzerland/Poland)
Webinar 2
The 2019 ESC–EAS Dyslipidaemia Guidelines Explained: What They Mean for Patients
📅 19 February 2026 | 6:00 pm CET 👉 Register here
This session provides a patient-friendly explanation of the 2019 ESC–EAS Dyslipidaemia Guidelines, including their rationale, key recommendations, and challenges in real-world implementation.
Key topics include:
- Why dyslipidaemia guidelines were needed in 2019
- Who the guidelines apply to (risk groups, familial hypercholesterolaemia, secondary prevention)
- LDL-C targets and cardiovascular risk stratification
- Lifestyle and pharmacological therapies
- Implementation gaps and access challenges
- Patient experiences and barriers
- Recommendations for FCS and HoFH
Speakers
- Dr. Julia Brandts, University Hospital Aachen (Germany)
- Dr. Antonio Gallo, La Pitié-Salpêtrière Hospital, AP-HP (France)
- Patient representative: Neeraja Venu (Germany/India)
- Moderated by Dr. Marina Leroy, Scientific Communications Manager, FH Europe Foundation (Switzerland/France)
Webinar 3
What’s New in 2025? Understanding the Latest ESC–EAS Dyslipidaemia Guidelines Focused Update
📅 26 February 2026 | 6:00 pm CET 👉 Register here
The final webinar explains what has changed in the 2025 focused update of the ESC–EAS Dyslipidaemia Guidelines, why these changes were made, and what they mean for patients now and in the future.
Key topics include:
- Why a focused update was required
- New evidence influencing the 2025 recommendations
- Key changes compared with the 2019 guidelines
- Implications for patients already receiving treatment
- Emerging therapies and future directions
Speakers
- Prof. Janine Roeters van Lennep, Professor of Cardiovascular Prevention, Erasmus MC (Netherlands)
- Prof. Florian Kronenberg, Head of the Institute of Genetic Epidemiology at the Medical University of Innsbruck (Austria)
- Patient representative: Marius Scheepers (United Kingdom/South Africa)
- Moderated by Elsie Evans, Ambassador Programme Project Manager, FH Europe Foundation (United Kingdom/South Africa)
